Redeye keeps its Base Case unchanged and makes minor estimate revisions following a Q2 report roughl...
Redeye gives its initial take on BONESUPPORT’s Q2 report.
We expect double-digit earnings growth from Q4 Q2 was characterised by a stable organic performance ...
Q2 expectations Prevas will release its Q2'25 report on 17 July, and we expect SEK 428m in sales, im...
Top-line miss weighs on Q2 numbers FastPartner delivered Q2 results with rental income and net opera...
Redeye nudges down its estimates and valuation following Lifco’s Q2 2025 report.
Redeye updates its estimates and valuation following OEM’s Q2 2025 report.
Redeye provides its initial take on Indutrade’s Q2 2025 report, which came in below our estimates.
Ahead of Atria's Q2 report, we maintain our estimates intact.
Recycling momentum continues Nexam reported sales of SEK 54m, +1% y-o-y and -1% vs.
Huge share price potential must be balanced against large risks in this exciting mine developer.
Plejd rapporterade för andra kvartalet 2025 en nettoomsättning om 210,7 MSEK (146,2), motsvarande en...
Redeye raises its base case following Xspray’s announcement that XS003 has achieved bioequivalence w...
Redeye lowers its estimates and valuation following Vitec’s Q2 2025 report.
Market headwinds worsened by accounting effects Careium delivered soft sales in Q2, with organic gro...
